We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

Studies in the Pharmacodynamics of Mechlorethamine and AB 100

Robert K. Ausman, M.D.; George E. Crevar, M.S.; Herman Hagedorn, B.S.; T. J. Bardos, Ph.D.; J. L. Ambrus, M.D., Ph.D.
JAMA. 1961;178(7):735-738. doi:10.1001/jama.1961.73040460013007e.
Text Size: A A A
Published online


ALKYLATING agents have been used in the Ltreatment of neoplastic disease since 1931, when Adair and Bagg1 described experiences with topical application of sulfur mustard. Intensive investigation during World War II resulted in a greater appreciation of the usefulness of these compounds. Pharmacological studies of mechlorethamine (methyl-bis [β-chloroethyl] amine) hydrochloride have been conducted almost entirely with biological tests, relying upon the lethality of the agent in the experimental animal to indicate potency.

Recently, a colorimetric chemical determination has been developed2 by which it is possible to quantitate the presence of alkylating agents in aqueous biological media. With this test, many aspects of the basic reactions of mechlorethamine have been studied in order to confirm or repudiate concepts established by less accurate techniques.

To gain knowledge as to the final applicability of the alkylating agent test and to determine its potential importance regarding the testing of new alkylating substances


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.